Cancer Moonshot℠ - Funding by Research Category
To ensure the Cancer Moonshot goals and approaches were grounded in the best science, NCI convened a Blue Ribbon Panel (BRP) of scientific experts as a working group to the National Cancer Advisory board. In September of 2016, the BRP presented a final report outlining 10 research recommendations that represent areas that are well-positioned to accelerate progress in cancer prevention, diagnosis, treatment and care.
The following research categories align with these 10 recommendations:
|Network for Direct Patient Engagement||$53,968,535|
|Cancer Immunotherapy Translational Science Network||
|Therapeutic Target Identification to Overcome Drug Resistance||
|A National Cancer Data Ecosystem for Sharing and Analysis||
|Fusion Oncoproteins in Childhood Cancers||
|Minimize Cancer Treatment’s Debilitating Side Effects||
|Prevention and early detection: Implementation of Evidence-Based Approaches||
|Retrospective Analysis of Biospecimens form Patients Treated with Standard of Care||
|Generation of Human Tumor Atlases||
|Development of New Enabling Cancer Technologies||
|Other Cancer Moonshot priority activities (e.g., Partnership for Accelerating Cancer Therapies)||
1 Includes new obligations and recoveries from fiscal years 2017, 2018, 2019 and 2020 carryover accounts.